Search

Your search keyword '"Liu, Xiaoye"' showing total 404 results
Start Over Author "Liu, Xiaoye"
404 results on '"Liu, Xiaoye"'

1. Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells

Author

Lian, Xizhen, Chatterjee, Sumanta, Sun, Yehui, Dilliard, Sean A., Moore, Stephen, Xiao, Yufen, Bian, Xiaoyan, Yamada, Kohki, Sung, Yun-Chieh, Levine, Rachel M., Mayberry, Kalin, John, Samuel, Liu, Xiaoye, Smith, Caroline, Johnson, Lindsay T., Wang, Xu, Zhang, Cheng Cheng, Liu, David R., Newby, Gregory A., Weiss, Mitchell J., Yen, Jonathan S., and Siegwart, Daniel J.

Published
2024
Full Text
View/download PDF

4. Identification of FDA-approved drugs that induce heart regeneration in mammals

Author

Ahmed, Mahmoud Salama, Nguyen, Ngoc Uyen Nhi, Nakada, Yuji, Hsu, Ching-Cheng, Farag, Ayman, Lam, Nicholas T., Wang, Ping, Thet, Suwannee, Menendez-Montes, Ivan, Elhelaly, Waleed M., Lou, Xi, Secco, Ilaria, Tomczyk, Mateusz, Zentilin, Lorena, Pei, Jimin, Cui, Miao, Dos Santos, Matthieu, Liu, Xiaoye, Liu, Yan, Zaha, David, Walcott, Gregory, Tomchick, Diana R., Xing, Chao, Zhang, Cheng Cheng, Grishin, Nick V., Giacca, Mauro, Zhang, Jianyi, and Sadek, Hesham A.

Published
2024
Full Text
View/download PDF

23. Genome-Wide Identification of the Soybean AlkB Homologue Gene Family and Functional Characterization of GmALKBH10Bs as RNA m 6 A Demethylases and Expression Patterns under Abiotic Stress.

Author

Zhao, Jie, Yang, Tengfeng, Liu, Peng, Liu, Huijie, Zhang, Hui, Guo, Sichao, Liu, Xiaoye, Chen, Xiaoguang, and Chen, Mingjia

Abstract

Soybean (Glycine max (L.) Merr) is one of the most important crops worldwide, but its yield is vulnerable to abiotic stresses. In Arabidopsis, the AlkB homologue (ALKBH) family genes plays a crucial role in plant development and stress response. However, the identification and functions of its homologous genes in soybean remain obscured. Here, we identified a total of 22 ALKBH genes in soybean and classified them into seven subfamilies according to phylogenetic analysis. Gene duplication events among the family members and gene structure, conserved domains, and motifs of all candidate genes were analyzed. By comparing the changes in the m6A levels on mRNA from hair roots between soybean seedlings harboring the empty vector and those harboring the GmALKBH10B protein, we demonstrated that all four GmALKBH10B proteins are bona fide m6A RNA demethylases in vivo. Subcellular localization and expression patterns of the GmALKBH10B revealed that they might be functionally redundant. Furthermore, an analysis of cis-elements coupled with gene expression data demonstrated that GmALKBH10B subfamily genes, including GmALKBH10B1, GmALKBH10B2, GmALKBH10B3, and GmALKBH10B4, are likely involved in the cis-elements' response to various environmental stimuli. In summary, our study is the first to report the genome-wide identification of GmALKBH family genes in soybean and to determine the function of GmALKBH10B proteins as m6A RNA demethylases, providing insights into GmALKBH10B genes in response to abiotic stresses. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Probio‐M9, a breast milk‐originated probiotic, alleviates mastitis and enhances antibiotic efficacy: Insights into the gut–mammary axis.

Author

Yu, Jie, Li, Weicheng, Xu, Ruibo, Liu, Xiaoye, Gao, Guangqi, Kwok, Lai‐Yu, Chen, Yongfu, Sun, Zhihong, Liu, Wenjun, and Zhang, Heping

Subjects
PEARSON correlation (Statistics), LABORATORY rats, WHOLE genome sequencing, MAMMARY glands, SINGLE nucleotide polymorphisms
Abstract

A study examined the use of a probiotic called Probio-M9 in treating mastitis and improving antibiotic treatment. The researchers found that Probio-M9 effectively reduced mastitis symptoms, decreased inflammation, and enhanced the response to antibiotics. It also had an impact on the gut microbiome and the immune system. The study suggests that Probio-M9 can move from the gut to the mammary tissue during bacterial mastitis and lactation. These findings provide insight into the connection between the gut and mammary glands and the potential benefits of probiotics. [Extracted from the article]

Published
2024
Full Text
View/download PDF

26. Supplementary Fig. 1B from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development

Author

Huang, Ryan, primary, Liu, Xiaoye, primary, Kim, Jaehyup, primary, Deng, Hui, primary, Deng, Mi, primary, Gui, Xun, primary, Chen, Heyu, primary, Wu, Guojin, primary, Xiong, Wei, primary, Xie, Jingjing, primary, Lewis, Cheryl, primary, Homsi, Jade, primary, Yang, Xing, primary, Zhang, Chengcheng, primary, He, Yubo, primary, Lou, Qi, primary, Smith, Caroline, primary, John, Samuel, primary, Zhang, Ningyan, primary, An, Zhiqiang, primary, and Zhang, Cheng Cheng, primary

Published
2024
Full Text
View/download PDF

27. Data from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development

Author

Huang, Ryan, primary, Liu, Xiaoye, primary, Kim, Jaehyup, primary, Deng, Hui, primary, Deng, Mi, primary, Gui, Xun, primary, Chen, Heyu, primary, Wu, Guojin, primary, Xiong, Wei, primary, Xie, Jingjing, primary, Lewis, Cheryl, primary, Homsi, Jade, primary, Yang, Xing, primary, Zhang, Chengcheng, primary, He, Yubo, primary, Lou, Qi, primary, Smith, Caroline, primary, John, Samuel, primary, Zhang, Ningyan, primary, An, Zhiqiang, primary, and Zhang, Cheng Cheng, primary

Published
2024
Full Text
View/download PDF

28. Supplementary Tables from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development

Author

Huang, Ryan, primary, Liu, Xiaoye, primary, Kim, Jaehyup, primary, Deng, Hui, primary, Deng, Mi, primary, Gui, Xun, primary, Chen, Heyu, primary, Wu, Guojin, primary, Xiong, Wei, primary, Xie, Jingjing, primary, Lewis, Cheryl, primary, Homsi, Jade, primary, Yang, Xing, primary, Zhang, Chengcheng, primary, He, Yubo, primary, Lou, Qi, primary, Smith, Caroline, primary, John, Samuel, primary, Zhang, Ningyan, primary, An, Zhiqiang, primary, and Zhang, Cheng Cheng, primary

Published
2024
Full Text
View/download PDF

29. Supplementary Fig. 2 from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development

Author

Huang, Ryan, primary, Liu, Xiaoye, primary, Kim, Jaehyup, primary, Deng, Hui, primary, Deng, Mi, primary, Gui, Xun, primary, Chen, Heyu, primary, Wu, Guojin, primary, Xiong, Wei, primary, Xie, Jingjing, primary, Lewis, Cheryl, primary, Homsi, Jade, primary, Yang, Xing, primary, Zhang, Chengcheng, primary, He, Yubo, primary, Lou, Qi, primary, Smith, Caroline, primary, John, Samuel, primary, Zhang, Ningyan, primary, An, Zhiqiang, primary, and Zhang, Cheng Cheng, primary

Published
2024
Full Text
View/download PDF

30. Supplementary Fig. 3 from LILRB3 Supports Immunosuppressive Activity of Myeloid Cells and Tumor Development

Author

Huang, Ryan, primary, Liu, Xiaoye, primary, Kim, Jaehyup, primary, Deng, Hui, primary, Deng, Mi, primary, Gui, Xun, primary, Chen, Heyu, primary, Wu, Guojin, primary, Xiong, Wei, primary, Xie, Jingjing, primary, Lewis, Cheryl, primary, Homsi, Jade, primary, Yang, Xing, primary, Zhang, Chengcheng, primary, He, Yubo, primary, Lou, Qi, primary, Smith, Caroline, primary, John, Samuel, primary, Zhang, Ningyan, primary, An, Zhiqiang, primary, and Zhang, Cheng Cheng, primary

Published
2024
Full Text
View/download PDF

34. Can low‐dose intravenous bevacizumab be as effective as high‐dose bevacizumab for cerebral radiation necrosis?

Author

Gao, Miaomiao, primary, Wang, Xin, additional, Wang, Xiaofeng, additional, Niu, Gengmin, additional, Liu, Xiaoye, additional, Zhao, Shuzhou, additional, Wang, Yue, additional, Yu, Huiwen, additional, Huo, Siyuan, additional, Su, Hui, additional, Song, Yongchun, additional, Wang, Xiaoguang, additional, Zhuang, Hong‐Qing, additional, and Yuan, Zhi‐Yong, additional

Published
2023
Full Text
View/download PDF

35. LILRB3 supports immunosuppressive activity of myeloid cells and tumor development

Author

Huang, Ryan, primary, Liu, Xiaoye, additional, Kim, Jaehyup, additional, Deng, Hui, additional, Deng, Mi, additional, Gui, Xun, additional, Chen, Heyu, additional, Wu, Guojin, additional, Xiong, Wei, additional, Xie, Jingjing, additional, Lewis, Cheryl, additional, Homsi, Jade, additional, Yang, Xing, additional, Zhang, Chengcheng, additional, He, Yubo, additional, Lou, Qi, additional, Smith, Caroline, additional, John, Samuel, additional, Zhang, Ningyan, additional, and An, Zhiqiang, additional

Published
2023
Full Text
View/download PDF

45. Can low‐dose intravenous bevacizumab be as effective as high‐dose bevacizumab for cerebral radiation necrosis?

Author

Gao, Miaomiao, Wang, Xin, Wang, Xiaofeng, Niu, Gengmin, Liu, Xiaoye, Zhao, Shuzhou, Wang, Yue, Yu, Huiwen, Huo, Siyuan, Su, Hui, Song, Yongchun, Wang, Xiaoguang, Zhuang, Hong‐Qing, and Yuan, Zhi‐Yong

Abstract

Although intravenous bevacizumab (IVBEV) is the most promising treatment for cerebral radiation necrosis (CRN), there is no conclusion on the optimal dosage. Our retrospective study aimed to compare the efficacy and safety of high‐dose with low‐dose IVBEV in treating CRN associated with radiotherapy for brain metastases (BMs). This paper describes 75 patients who were diagnosed with CRN secondary to radiotherapy for BMs, treated with low‐dose or high‐dose IVBEV and followed up for a minimum of 6 months. The clinical data collected for this study include changes in brain MRI, clinical symptoms, and corticosteroid usage before, during, and after IVBEV treatment. At the 3‐month mark following administration of IVBEV, a comparison of two groups revealed that the median percentage decreases in CRN volume on T2‐weighted fluid‐attenuated inversion recovery and T1‐weighted gadolinium contrast‐enhanced image (T1CE), as well as the signal ratio reduction on T1CE, were 65.8% versus 64.8% (p = 0.860), 41.2% versus 51.9% (p = 0.396), and 37.4% versus 35.1% (p = 0.271), respectively. Similarly, at 6 months post‐IVBEV, the median percentage reductions of the aforementioned parameters were 59.5% versus 62.0% (p = 0.757), 39.1% versus 31.3% (p = 0.851), and 35.4% versus 28.2% (p = 0.083), respectively. Notably, the incidence of grade ≥3 adverse events was higher in the high‐dose group (n = 4, 9.8%) than in the low‐dose group (n = 0). Among patients with CRN secondary to radiotherapy for BMs, the administration of high‐dose IVBEV did not demonstrate superiority over low‐dose IVBEV. Moreover, the use of high‐dose IVBEV was associated with a higher incidence of grade ≥3 adverse events compared with low‐dose IVBEV. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results